Tag: Pasireotide

As of early 2020, studies showed that a significant portion of patients on first-generation somatostatin analogues (SSAs) for acromegaly had an inadequate response to treatment. When primary therapy fails, or for reasons of tolerance or administration, knowing what is a substitute for octreotide becomes crucial for effective patient care.

The body's natural hormone, somatostatin, has an extremely short half-life of only 1–3 minutes, making it unsuitable for clinical use. A **somatostatin analog** (SSA) is a synthetic version of this hormone designed with a significantly longer half-life to provide sustained therapeutic benefits in a clinical setting.